Synthesis and Structure鈥揂ctivity Relationships of (Aryloxy)quinazoline Ureas as Novel, Potent, and Selective Vascular Endothelial Growth Factor Receptor-2 Inhibitors

详细信息    查看全文

• 作者：Antonio Garofalo ; Amaury Farce ; S茅verine Ravez ; Am茅lie Lemoine ; Perrine Six ; Philippe Chavatte ; Laurence Goossens ; Patrick Depreux
• 刊名：Journal of Medicinal Chemistry
• 出版年：2012
• 出版时间：February 9, 2012
• 年：2012
• 卷：55
• 期：3
• 页码：1189-1204
• 全文大小：612K
• 年卷期：v.55,no.3(February 9, 2012)
• ISSN：1520-4804

文摘

In our continuing search for medicinal agents to treat proliferative diseases, quinazoline derivatives were synthesized and evaluated pharmacologically as epithelial growth factor receptor and vascular endothelial growth factor receptor 2 (VEGFR-2) tyrosine kinase inhibitors. A quantitative structure鈥揳ctivity relationship analysis was conducted to rationalize the structure鈥揳ctivity relationship and to predict how similar the inhibitor-binding profiles of two protein kinases are likely to be on the basis of the docking of lead coumpounds into the ATP-binding site. This model was used to direct the synthesis of new compounds. A series of N-(aromatic)-N鈥?/i>-{4-[(6,7-dimethoxyquinazolin-4-yl)oxy]phenyl}urea were identified as potent and selective inhibitors of the tyrosine kinase activity of VEGFR-2 (fetal liver kinase 1, kinase insert domain-containing receptor). An efficient route was developed that enabled the synthesis of a wide variety of analogues with substitution on several positions of the template. Substitution of diarylurea, competitive with ATP, afforded several analogues with low nanomolar inhibition of enzymatic activity of VEGFR-2. In this paper, we describe the synthesis, structure鈥揳ctivity relationships, and pharmacological characterization of the series.